PT  - JOURNAL ARTICLE
AU  - Pulliam, Juliet R.C.
AU  - van Schalkwyk, Cari
AU  - Govender, Nevashan
AU  - von Gottberg, Anne
AU  - Cohen, Cheryl
AU  - Groome, Michelle J.
AU  - Dushoff, Jonathan
AU  - Mlisana, Koleka
AU  - Moultrie, Harry
TI  - Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa
AID  - 10.1101/2021.11.11.21266068
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.11.21266068
4099  - http://medrxiv.org/content/early/2021/12/02/2021.11.11.21266068.short
4100  - http://medrxiv.org/content/early/2021/12/02/2021.11.11.21266068.full
AB  - Objective To examine whether SARS-CoV-2 reinfection risk has changed through time in South Africa, in the context of the emergence of the Beta, Delta, and Omicron variantsDesign Retrospective analysis of routine epidemiological surveillance dataSetting Line list data on SARS-CoV-2 with specimen receipt dates between 04 March 2020 and 27 November 2021, collected through South Africa’s National Notifiable Medical Conditions Surveillance SystemParticipants 2,796,982 individuals with laboratory-confirmed SARS-CoV-2 who had a positive test result at least 90 days prior to 27 November 2021. Individuals having sequential positive tests at least 90 days apart were considered to have suspected reinfections.Main outcome measures Incidence of suspected reinfections through time; comparison of reinfection rates to the expectation under a null model (approach 1); empirical estimates of the time-varying hazards of infection and reinfection throughout the epidemic (approach 2)Results 35,670 suspected reinfections were identified among 2,796,982 individuals with laboratory-confirmed SARS-CoV-2 who had a positive test result at least 90 days prior to 27 November 2021. The number of reinfections observed through the end of the third wave was consistent with the null model of no change in reinfection risk (approach 1). Although increases in the hazard of primary infection were observed following the introduction of both the Beta and Delta variants, no corresponding increase was observed in the reinfection hazard (approach 2). Contrary to expectation, the estimated hazard ratio for reinfection versus primary infection was lower during waves driven by the Beta and Delta variants than for the first wave (relative hazard ratio for wave 2 versus wave 1: 0.75 (CI95: 0.59–0.97); for wave 3 versus wave 1: 0.71 (CI95: 0.56–0.92)). In contrast, the recent spread of the Omicron variant has been associated with a decrease in the hazard coefficient for primary infection and an increase in reinfection hazard coefficient. The estimated hazard ratio for reinfection versus primary infection for the period from 1 November 2021 to 27 November 2021 versus wave 1 was 2.39 (CI95: 1.88–3.11).Conclusion Population-level evidence suggests that the Omicron variant is associated with substantial ability to evade immunity from prior infection. In contrast, there is no population-wide epidemiological evidence of immune escape associated with the Beta or Delta variants. This finding has important implications for public health planning, particularly in countries like South Africa with high rates of immunity from prior infection. Urgent questions remain regarding whether Omicron is also able to evade vaccine-induced immunity and the potential implications of reduced immunity to infection on protection against severe disease and death.Box 1What is already known on this topicWhat is already known on this topicPrior infection with SARS-CoV-2 is estimated to provide at least an 80% reduction in infection risk (1,2).Laboratory-based studies indicate reduced neutralization by convalescent serum for the Beta and Delta variants relative to wild type virus (3–6); however, the impact of these reductions on risk of reinfection is not known, and laboratory assessments of Omicron are still underway.What this study addsWhat this study addsWe provide two methods for monitoring reinfection trends to identify signatures of changes in reinfection risk.We find no evidence of increased reinfection risk associated with circulation of Beta or Delta variants compared to the ancestral strain in routine epidemiological data from South Africa.In contrast, we find clear, population-level evidence to suggest substantial immune evasion by the Omicron variant.One sentence summary Analysis of routine surveillance data from South Africa suggests that, in contrast to the Beta and Delta, the Omicron variant of SARS-CoV-2 demonstrates substantial population-level evidence for evasion of immunity from prior infection.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form. CC and AvG have received funding from Sanofi Pasteur in the past 36 months. JRCP and KM serve on the Ministerial Advisory Committee on COVID-19 of the South African National Department of Health. The authors have declared no other relationships or activities that could appear to have influenced the submitted work.Funding StatementThis work was supported by the South African Department of Science and Innovation and the National Research Foundation and the Wellcome Trust (grant number 221003/Z/20/Z) in collaboration with the Foreign, Commonwealth and Development Office, United Kingdom.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has received ethical clearance from University of the Witwatersrand (Clearance certificate number M210752, formerly M160667) and approval under reciprocal review from Stellenbosch University (Project ID 19330, Ethics Reference Number N20/11/074_RECIP_WITS_M160667_COVID-19).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData and code will be made available at https://github.com/jrcpulliam/reinfections. The following data are included in the repository: - Counts of reinfections and primary infections by province, age group (5-year bands), and sex (M, F, U) - Daily time series of primary infections and suspected reinfections by specimen receipt date (national) - Model output: posterior samples from the MCMC fitting procedure and simulation results Requests for additional data must be made in writing to the National Institute for Communicable Diseases, South Africa. https://github.com/jrcpulliam/reinfections